This systematic evidence-based review by the American Society for Blood and Marrow Transplantation (ASBMT) evaluated the role of hematopoietic cell transplantation (HCT) in the treatment of Hodgkin lymphoma (HL) in pediatric and adult populations. The recommendations were unanimously agreed upon by a panel of HL experts. The report noted that the standard of clinical care includes both autologous and allogeneic HCT with a survival benefit shown in selected patients with advanced or relapsed HL. Relapse remains a concern after both transplant approaches and strategies to decrease this risk should be investigated.
ASBMT Evidence-Based Review: The Role of HCT in Hodgkin Lymphoma